The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies

Meng Michelle Xu, Yang Pu, Yuan Zhang, Yang Xin Fu

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.

Original languageEnglish (US)
Pages (from-to)141-153
Number of pages13
JournalTrends in Immunology
Issue number2
StatePublished - Feb 1 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies'. Together they form a unique fingerprint.

Cite this